Evidence map›Paper›PMID 40316776›Full record

ArticleCommunications biology2025

CD55 upregulation in T cells of COVID-19 patients suppresses type-I interferon responses.

Maria G Detsika, Maria Sakkou, Vassiliki Triantafyllidou, Dimitris Konstantopoulos, Eirini Grigoriou, Katherina Psarra, Edison Jahaj, Ioanna Dimopoulou, Stylianos E Orfanos, Alexandra Tsirogianni and 2 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maria G Detsika1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, Athens, Greece. mdetsika@med.uoa.gr.ORCID http://orcid.org/0000-0003-4425-235X
Maria SakkouInstitute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.
Vassiliki TriantafyllidouInstitute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.
Dimitris KonstantopoulosInstitute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.ORCID http://orcid.org/0000-0003-2142-3021
Eirini GrigoriouDepartment of Immunology and Histocompatibility, 'Evangelismos' General Hospital, Athens, Greece.
Katherina PsarraDepartment of Immunology and Histocompatibility, 'Evangelismos' General Hospital, Athens, Greece.
Edison Jahaj1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0002-7306-713X
Ioanna Dimopoulou1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Stylianos E Orfanos1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Alexandra TsirogianniDepartment of Immunology and Histocompatibility, 'Evangelismos' General Hospital, Athens, Greece.
George KolliasInstitute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece.ORCID http://orcid.org/0000-0003-1867-3150
Anastasia Kotanidou1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, Athens, Greece. akotanid@med.uoa.gr.ORCID http://orcid.org/0000-0002-2508-500X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complement overactivation, has been verified in COVID-19 patients. Complement regulatory proteins, including CD55, control complement overactivation thus eliminating complement deposition and cell lysis. We investigated complement regulatory protein expression in COVID-19 for potential deregulated expression patterns driving disease pathogenesis. Single-cell RNA-seq revealed increased PBMCs CD55 expression in severely and critically ill patients. This increase was also detected upon integrated subclustering analysis of monocyte, T cell and B cell populations. FACS analysis confirmed the significant upregulation of CD55 expression in CD4

Indexed as

CD55 AntigensCOVID-19Interferon Type IT-LymphocytesAdultAgedFemaleHumansMaleMiddle AgedSARS-CoV-2Up-RegulationCD55 AntigensInterferon Type I

Identifiers

PMID40316776
PMCPMC12048498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.